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Abstract
Background: Single nucleotide polymorphisms (SNPs) in the Plasmodium vivax dihydrofolate reductase (Pfdhfr) and
dihydropteroate synthetase (Pvdhps) genes cause parasite resistance to the antifolate drug combination, sulphadoxine/
pyrimethamine (SP). Monitoring these SNPs provide insights into the level of drug pressure caused by SP use and
presumably other antifolate drugs. In Sri Lanka, chloroquine (CQ) with primaquine (PQ) and SP with PQ is used as first
and second line treatment, respectively, against uncomplicated Plasmodium falciparum and/or P. vivax infections. CQ/PQ
is still efficacious against P. vivax infections, thus SP is rarely used and it is assumed that the prevalence of SNPs related
to P. vivax SP resistance is low. However, this has not been assessed in Sri Lanka as in most other parts of Asia. This study
describes the prevalence and distribution of SNPs related to P. vivax SP resistance across Sri Lanka.
Subjects and methods: P. vivax-positive samples were collected from subjects presenting at government health
facilities across nine of the major malaria endemic districts on the island. The samples were analysed for SNPs/haplotypes
at codon 57, 58, 61 and 117 of the Pvdhfr gene and 383, 553 and 585 of the Pvdhps gene by applying PCR followed by a
hybridization step using sequence specific oligonucleotide probes (SSOPs) in an ELISA format.
Results: In the study period, the government of Sri Lanka recorded 2,149 P. vivax cases from the nine districts out of
which, 454 (21.1%) blood samples were obtained. Pvdhfr haplotypes could be constructed for 373 of these. The FSTS
wild-haplotype was represented in 257 samples (68.9%), the double mutant LRTS haplotype was the most frequently
observed mutant (24.4%) while the triple mutation (LRTN) was only identified once. Except for two samples of the single
mutated Pvdhps GAV haplotype, the remaining samples were wildtype. Geographical differences were apparent, notably
a significantly higher frequency of mutant Pvdhfr haplotypes was observed in the Northern districts.
Conclusion: Since SP is rarely used in Sri Lanka, the high frequency and diversity of Pvdhfr mutations was unexpected
indicating the emergence of drug resistant parasites despite a low level of SP drug pressure.
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Background
Plasmodium vivax is the most geographically widespread of
the four Plasmodium species infective to humans found
throughout South and Central America, Asia, the Middle
East, and parts of Africa and infects an estimated 70–80
million people annually [1]. Chloroquine (CQ)-resistant
Plasmodium falciparum, and to a lesser extent CQ resistant
P. vivax, is almost as endemic as malaria itself and alterna-
tives such as the drug combination sulphadoxine/
pyrimethamine (SP) have replaced CQ. Resistance to SP
has recently emerged for P. falciparum, while for P. vivax it
has been observed sporadically [2]. The molecular mech-
anisms involved in the development of SP resistance of
the two species are most likely similar [3,4]. In P. falci-
parum, single nucleotide polymorphisms (SNPs) in codon
(c) 51, c59 and c108 of the Pfdhfr gene and in c437 and
c540 of Pfdhps  gene provide pyrimethamine and sul-
phadoxine resistance, respectively and these SNPs com-
bined result in high risk of SP treatment failure in vivo [5].
For  P. vivax, the picture is more complex because
pyrimethamine resistance possibly involve several SNPs
[6]. However, some evidence support that resistance is
mainly associated with mutations at c58 (S58R, occurring
as two SNPs, either AGA (R1) or AGG (R2)) and c117
(S117N or S117T) with additional mutations at c57
(F57L-existing as three SNPs, CTC (L1), TTG (L2) and TTA
(L3)) and c61 (T61M) in the Pvdhfr gene [3,4,6-8]. The
quadruple mutant haplotype (57L+58R+61M+117T) has
been shown to correlate with SP treatment failure in vivo
[8] and increases P. vivax resistance to pyrimethamine by
more than 500 times [4,6].
Presumably, P. vivax sulphadoxine resistance is caused by
SNPs in the Pvdhps gene. Based on homology models of
both P. falciparum and P. vivax DHPS enzymes, Korsinczky
et al. predicted that the P. vivax wildtype at c585 (V585)
possibly cause some level of innate sulphadoxine resist-
ance, while SNPs at c383 (A383G) and c553 (A553G) in
Pvdhps most likely increase resistance levels [9]. Imwong
et al. showed that only in regions with high SP usage, SNPs
in both Pvdhfr  and  Pfdhps  were observed and, further-
more, parasites harbouring multiple mutations in Pvdhfr
and Pvdhps were cleared more slowly from the blood of
patients following SP treatment [10]. Therefore, P. vivax
SP resistance is most likely measurable by examining the
frequency of SNPs in both the Pvdhfr and Pvdhps genes.
In Sri Lanka, CQ plus primaquine (PQ) and SP plus PQ
are used as 1st- and 2nd-line treatment, respectively,
against uncomplicated malaria infections, although CQ
resistant P. falciparum infections have been reported since
1984 and P. falciparum SP resistance has been observed
recently [11]. P. vivax resistance to either CQ or SP has not
been recorded on the island. This study investigated the
frequency of SNPs/haplotypes in the Pvdhfr (at c57, 58, 61
and 117) and Pvdhps (at c383, 553 and 585) genes in sam-
ples collected from nine districts with endemic P. vivax
malaria in Sri Lanka over a 1 1/2-year period. The detec-
tion of SNPs/haplotypes in Pvdhfr and Pvdhps was per-
formed by applying a new simple enzyme-linked
immunosorbent assay (ELISA) using sequence specific
oligonucleotide probes (SSOPs) similar to the method
detecting SNPs/haplotypes in P. falciparum dhfr, dhps and
crt [12].
Materials and methods
The samples originated from individuals seeking treat-
ment for malaria at government health facilities located in
nine different malarious district across Sri Lanka. In Sri
Lanka the great majority of individuals with perceived
malaria seek treatment at government facilities [13]. Sam-
ples were collected by routine staff at the facilities trained
by the Anti-Malaria Campaign (AMC) of Sri Lanka from
September 2004 to March 2006, thereby including the tra-
ditionally malaria peak transmission seasons in January
and one lower peak season around July. Finger prick
blood from patients with single P. vivax or mixed P. vivax/
P. falciparum infections, diagnosed by microscopy were
spotted on filter paper and sealed in individual zip-lock
bags. DNA extraction was carried out by the chelex-100
method as described in [12].
As positive controls of the various Pvdhfr  SNPs/haplo-
types, 8 P. vivax dhfr allele samples, kindly provided by
Carol Sibley (Dept. of Genome Sciences, University of
Washington) were used [4]. These represent each of the
ten most common c57, 58, 61 and 117 Pvdhfr SNPs/hap-
lotypes. Furthermore, one positive control consisting of a
50 bp DNA fragment was designed mimicking a specific
mutated Pvdhfr sequence, comprising the L3-mutation in
c57 (TTA) and R2-mutation in c58 (AGG) (PcL3R2T in
table 1) biotinylated at the 5'-end by the supplier (MWG
Biotech, Riskov, Denmark). Likewise for positive controls
of Pvdhps 338G and 553G, 50 bp DNA fragments were
designed mimicking these specific SNPs (Pc383G and
Pc553G in Table 1).
The outer and nested Pvdhfr  PCR protocols used are
described in [14], with the exception that the reverse
nested primer, KH-3R was biotinylated at the 5'-end by
the supplier (MWG Biotech, Riskov, Denmark). The outer
Pvdhps  PCR primers used (PvDHPS-D and PvDHPS-B)
and protocols are described by [9]. The nested Pvdhps
primers were designed; NL-1 (5'-GCGAGCGTGATTGA-
CATC-3') and NR-1-(5'-GCTCATCAGTCTGCACTCC-3')
where the reverse primer, NR-1, was biotinylated at the 5'-
end. The outer and nested Pvdhps PCR were performed as
follows: denaturation at 94°C for 2 min followed by 40
cycles of 94°C for 30 sec, 50°C for 30 sec and 65°C for 1
1/2 min and subsequently a 5 min extension step at 65°C.Malaria Journal 2007, 6:28 http://www.malariajournal.com/content/6/1/28
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A SSOP-ELISA, similar to the method for SNP/haplotype
analysis of P. falciparum dhfr/dhps  was developed [12],
however using pre-coated streptavidin plates (Nunc,
Roskilde, Denmark). The 3'-end digoxigenin-conjugated
SSOPs designed to target the most common Pvdhfr and
Pvdhps SNP/haplotypes including the time and tempera-
tures in the two rounds of high stringency washing with
tetra-methyl-ammonium chloride (TMAC) is given in
table 1. Scoring of ELISA data were performed as described
elsewhere [12]. To verify the results, Restriction Fragment
Length Polymorphism (RFLP) was performed on a subset
of the samples using enzymes and methods described by
[15]. Polymorphisms in c383 of the Pvdhps  gene were
identified by digestion with the restriction enzyme HaeIII
(New England Biolabs, Medinova, Glostrup, Denmark).
Sequencing was performed on a subset of samples to clar-
ify some of the Pvdhfr and Pvdhps haplotypes; PCR prod-
ucts with A-overhang were cloned into the TOPO TA
vector according to manufacturing procedures (Invitro-
gen), and plasmids were prepared using MiniPrep spin
columns (Omega Biotech). Sequencing was done on an
ABI Prism 377 (Perkin-Elmer) using the Big Dye termina-
tor reaction mix (Perkin-Elmer).
Ethical clearance for this project was granted by the Com-
mittee on Research and Ethical Review at the Faculty of
Medicine, Peradeniya, Kandy and verbal consent was
obtained from participants, parents and/or guardians.
Results
In the study period, AMC recorded a total of 2717 P. vivax
cases in the country, out of which, 2,149 cases came from
the nine districts included in this study (79.1%). 454
(21.1%) blood samples from these districts, representing
a large range of catchments efficiencies from 7.7% (Mon-
aragala) to 67.5% (Polonnaruwa) were examined. The
samples were analysed for SNPs/haplotypes at position
c57, 58, 61 and 117 of the Pvdhfr gene and c383, 553 and
585 (only detection of the wildtype V585) of the Pvdhps
gene using an array of SSOPs. Samples either repeatedly
PCR negative or negative in one or more of the Pvdhfr or
Pvdhps codons were omitted from the analysis.
For Pvdhfr, haplotypes could be constructed for 373 sam-
ples (84.6 %) including 25 samples with mixed haplotype
infections, but where a major haplotype could be deduced
(Figure 1). The Pvdhfr  FSTS wild haplotype was repre-
sented in 257 samples (68.9 %) while the remaining sam-
Table 1: The sequence specific oligonucleotide probes (SSOPs) targeting SNPs/haplotypes in c57, 58, 61 and 117 of the Pvdhfr gene and 
c383, 553 and 585 in the Pvdhps gene and artificial positive controls.
SSOP SSOP sequence † Washing temperature § Incubation time ¶
Pvdhfr (C°) Min.
57/58/61 FST AC TTC AGC TCG GTG ACG A6 0 1 2
57/58/61 FR1TA C   TTC AGA TCG GTG ACG A6 0 1 0
57/58/61 FR2TA C   TTC AGG TCG GTG ACG A6 0 1 0
57/58/61 L1R2MA C CTC AGG TCG GTG ATG A6 2 1 0
57/58/61 L2ST AC TTG AGC TCG GTG ACG A6 0 1 0
57/58/61 L2R1TA C   TTG AGA TCG GTGACG A6 4 1 0
57/58/61 L3R2TA C   TTA AGG TCG GTG ACG A6 2 1 0
117 S G AGA AGC AGC TGG GAG AG 60 12
117 N G AGA AGC AAC TGG GAG AG 60 10
117 T G AGA AGC ACC TGG GAG AG 60 10
Pvdhps
383A A TCG TCC GCC CCT TAT GT 64 10
c383 G A TCG TCC GGC CCT TAT GT 64 10
c553A TC GGC CTG GGG TTTGCC A6 4 1 0
c553G TC GGC CTG GGG TTTGGC A6 4 1 0
c585V C TTT ATT GTC CAC TGC AT 64 10
Positive controls*
Pvdhfr Sequence
PcL3R2T TCCGTCGATATGAAGTACTTAAGGTCGGTGACGACCTACGTGGATGAGTC
Pvdhps
Pc383G GATTGACATCGGGGGGGAATCGTCCGGCCCTTATGTGGTCCCCAATCCGA
Pc553G CTTTGATGTCGGCCTGGGGTTTGGCAAAAAGCACGACCAGTCTATTAAGC
† Sequences in bold indicate the codon in which the SNP occurs.
§ Optimal TMAC-washing temperature.
¶ Optimal incubation time for TMAC-wash
* Artificial positive controls mimicking specific mutated Pvdhfr or Pvdhps sequences.Malaria Journal 2007, 6:28 http://www.malariajournal.com/content/6/1/28
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ples comprised of five different mutant haplotypes at c57,
58 and 117 only: as F57L3  (TTC→TTA), S58R2
(AGC→AGG) and S117N. The double mutant LRTS hap-
lotype was the most frequently mutated haplotype,
observed in the districts Anuradhapura (frequency (f):
0.05, n = 10), Trincomalee (f: 0.52, n = 29), Pollonaruwa
(f: 0.18, n = 9), Batticaloa (f: 0.43, n = 6), Kurunegala (f:
0.71, n = 34) and Ampara (f: 0.43, n = 3). The 117N muta-
tion was less frequently observed (in total: f: 0.06, n = 21),
as either the single mutated haplotype FSTN (only in Pol-
onnaruwa and Anuradhapura), the double mutated hap-
lotype, FRTN (only in the Northern districts of Mannar,
Vavuniya and Trincomalee). The triple mutation (LRTN)
was only identified once in the district Pollonaruwa and
as a mixture of LRTN/LRTS with the LRTN in majority. A
significantly higher frequency of mutant haplotypes
(FSTN, FRTN and LRTS) was observed in the Northern dis-
tricts (Mannar, Trincomalee and Vavuniya) compared to
the other districts (χ2 = 36.3, P ≤ 0.001). There was a gen-
eral tendency for an increase in the frequency of mutant
haplotypes late in the study period. However, due to a
skewed temporal collection of samples from the various
districts the differences was not analysed further.
A subset of samples analysed by sequencing (mainly to
confirm the c57L3) and by digestion of c58 and 117 in the
Pvdhfr gene by RFLP confirmed the data obtained be the
Pvdhfr SSOP-ELISA.
The Pvdhps haplotypes could be constructed for 368 of the
373 Pvdhfr positive samples (98.7 %). Wildtype haplo-
types at c383, 553 and 585 (AAV) was seen in 366 of these
samples, while two samples from Trincomalee were of the
single mutated GAV haplotype. These were confirmed by
sequencing. Both samples expressed the double mutated
FRTN haplotype in Pvdhfr.
Discussion
The present descriptive study analysed sulphadoxine/
pyrimethamine (SP) resistance-related SNPs in the P.
vivax dhfr and Pvdhps genes in samples originating from
nine districts in Sri Lanka, a country were both CQ and SP
(in combination with primaquine) is still regarded as effi-
cient treatment against uncomplicated P. falciparum and/
or P. vivax infections. The analysis identified six different
haplotypes of Pvdhfr while for Pvdhps, only wildtypes were
identified except for two cases.
The double mutant haplotype LRTS (F57L, S58R,
T61,117S) was the most frequent mutant haplotype and
not as expected as a combination of S117N and S58R
(FRTN) as observed previously [6,8,16] and in a recent
study from India [17]. The P. vivax triple mutant haplo-
type LRTN, previously found in Thailand and shown to be
associated with reduced ability of patients to decrease par-
asites ratios [15] was only found once and the quadruple
LRMT mutant haplotype causing a high risk of SP treat-
ment failures [8] was not detected, thus indicating that SP
(with primaquine) is still efficient against P. vivax infec-
tions in Sri Lanka. Nevertheless, it is surprising that almost
one third of the tested P. vivax infections were mutated in
the Pvdhfr gene, despite that, officially, SP is only used as
second-line drug against CQ treatment failures of P. falci-
parum. A recent study investigating the availability of SP in
privately-owned drug vendor shops in Sri Lanka found
that SP was virtually absent from the shops [18], thus the
specific drug pressure is unlikely to be caused by unau-
thorized use. More plausible, the mutations are not only
an indication of emerging pyrimethamine resistance, but
instead reflect the overall antifolate pressure in Sri Lanka.
Presently, antifolates such as dapsone, co-trimoxazole
and trimethoprim are for instance used against urinary
tract infections and chronic bronchitis on the island.
Alternatively, similar to development of P. falciparum
resistance to pyrimethamine in vivo, P. vivax populations
are occasionally exposed to sub-therapeutic levels of
pyrimethamine when re-infecting recently SP-treated
patients thereby providing optimal conditions for the
emergence of SP tolerant P. vivax parasites [19]. Thus,
even low drug pressure may facilitate the emergence of
drug tolerant/resistant parasites and this may particularly
be the case for P. vivax that to a larger extend than P. falci-
parum possibly can persist in the host unnoticed.
The frequency of Pvdhfr mutant haplotypes was signifi-
cantly higher in the most Northern regions (Mannar,
Vavuniya and Trincomalee) than the rest of the districts
examined. This might be indirectly caused by the civil
unrest resulting in a shortage of trained medical person-
nel, non-accurate malaria diagnosis and an underestima-
tion of malaria infections mainly in the Northern part of
Sri Lanka [20]. Furthermore, the FRTN haplotype was
only observed in the Northern districts and it may be spec-
ulated that human migration between Southern India and
the Northern part of Sri Lanka has introduced this partic-
ular haplotype from the Southern district of Chennai
where it is highly prevalent [17]. The limited number of
samples received from some districts, e.g. Monaragala,
Ampara, Batticaloa, Mannar and Vavuniya, limits inter-
pretation.
The high frequency of mutant haplotypes related to
pyrimethamine resistance is worrying because it indicates
that drug tolerant/resistant P. vivax parasites have evolved
despite a low level of SP drug pressure, possibly attributed
to the use of other antifolate drugs. It is not known
whether these mutant P. vivax haplotypes do exhibit SP
resistance in vivo.Malaria Journal 2007, 6:28 http://www.malariajournal.com/content/6/1/28
Page 5 of 6
(page number not for citation purposes)
The distribution of Plasmodium vivax dhfr haplotypes at c57 (F->L), 58 (S->R), 61 (T) and 117 (S->N) in samples collected from  P. vivax positive patients in 9 districts of Sri Lanka Figure 1
The distribution of Plasmodium vivax dhfr haplotypes at c57 (F->L), 58 (S->R), 61 (T) and 117 (S->N) in samples 
collected from P. vivax positive patients in 9 districts of Sri Lanka. The number in brackets is the actual number of P. 
vivax positive cases reported by Anti Malaria Campaign of Sri Lanka in the study period September 2004–March 2006. In red: 
the wild type to mutant type change in amino acids
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